Development of a targeted oral pharmacologic duodenal exclusion therapy for the treatment of metabolic diseases

Journal:

Science Advances

Published:

2025-05-30

DOI:

10.1126/sciadv.adu1326

Affiliations:

7

Authors:

11

Go to article

Institutions	Authors	Share
Glyscend, Inc., United States of America (USA)	6.333333	0.58
Clario, United States of America (USA)	1.000000	0.09
Boston University (BU), United States of America (USA)	1.000000	0.09
The University of Alabama at Birmingham (UAB), United States of America (USA)	1.000000	0.09
Mayo Clinic, United States of America (USA)	1.000000	0.09
Johns Hopkins Hospital, United States of America (USA)	0.666667	0.06

Interested in Pharmacology and Pharmaceutical Sciences?